Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark PPI Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy N/A

    Post Limit Prior Authorization Proton Pump Inhibitors

    Customize your policy alerts

    Sign up for all cvs_caremark policy alerts

    Know when cvs_caremark releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of additional quantities of specified proton pump inhibitors after the plan quantity limit is reached. Providers must document an accepted gastrointestinal indication or high risk for gastrointestinal adverse events for approval.

    Policy Summary
    PayerCVS Caremark
    PolicyPost Limit Prior Authorization Proton Pump Inhibitors
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewMar 27, 2025
    Next Review DateN/A
    Key ActionDocument a qualifying gastrointestinal condition, complication, or high risk for gastrointestinal adverse events when requesting quantities beyond 90 doses per 365 days.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    9PPI products referenced
    90 dosesPlan quantity before review
    3Approval pathways
    Lifetime/12 moMMT 918-J duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Lifetime/36 mo
    169-J duration

    Post-Limit Coverage Criteria

    Post-limit coverage criteria

    Authorization may be granted when ANY of the following criteria groups are met.

    Qualifying condition or risk

    • Specific gastrointestinal condition

      • Barrett's esophagus is confirmed by biopsy.
      • Hypersecretory syndrome, such as Zollinger-Ellison syndrome, is confirmed with a diagnostic test.
    • Peptic ulcer disease or GERD indication

      • Peptic ulcer disease is verified by endoscopy.
      • Chronic GERD symptoms: The patient has frequent and severe symptoms of chronic GERD.
      • Atypical or complicated GERD: The patient has atypical symptoms or complications of GERD, such as maintenance of healing of erosive esophagitis or duodenal ulcers.
    • High GI risk: The patient is at high risk for gastrointestinal adverse events.

      Risk factors include eosinophilic esophagitis, chronic NSAID therapy, history of peptic ulcer disease or GI bleeding, oral corticosteroid therapy, anticoagulant therapy, poor general health status, or advanced age.

    Over-the-counter products are excluded unless otherwise stated. The policy references both brand and generic proton pump inhibitor products, including all dosage forms and strengths unless otherwise specified.

    Quantity Limit

    Post-limit quantity
    Plan quantity limit90 doses per 365 days
    Post-limit reviewAdditional quantities are evaluated after the patient reaches the plan quantity limit.
    Additional-quantity requirementQuantities beyond the plan limit require documentation supporting the post-limit coverage criteria.

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Post-Limit Approval Pathway

    Submit the post-limit request when the patient meets at least one approval pathway: a qualifying gastrointestinal condition or complication, confirmed Barrett's esophagus or hypersecretory syndrome, or high risk for gastrointestinal adverse events.

    • The request must satisfy one of the documented post-limit approval pathways.
    Prior Authorization

    Post-Limit Review

    Review the request after the patient reaches the plan quantity limit of 90 doses per 365 days. Additional quantities require documentation supporting at least one post-limit approval criterion.

    • Plan limit: 90 doses per 365 days.
    • The prescriber may submit new or missing information for review.

    Clinical Background

    Proton pump inhibitors are used to treat acid-related gastrointestinal disorders, including GERD, erosive esophagitis, peptic ulcer disease, hypersecretory conditions, and prevention of selected NSAID-related complications. This policy addresses requests for quantities beyond the standard plan limit and focuses approval on patients with persistent, complicated, or high-risk gastrointestinal disease.

    Definitions and Referenced Products

    High risk for gastrointestinal adverse events
    DefinitionA condition in which the patient has an elevated risk for serious gastrointestinal adverse events.
    Risk factorsEosinophilic esophagitis; chronic nonsteroidal anti-inflammatory drug (NSAID) therapy; history of peptic ulcer disease and/or gastrointestinal bleeding; oral corticosteroid therapy.
    Additional risk factorsAnticoagulant therapy; poor general health status; or advanced age.
    Products referenced
    Products includedThe list includes both brand and generic products, including AcipHex (rabeprazole), AcipHex Sprinkles (rabeprazole), Dexilant (dexlansoprazole), Konvomep (omeprazole/sodium bicarbonate), Nexium (esomeprazole), Prevacid (lansoprazole), Prilosec (lansoprazole as listed), Protonix (pantoprazole), and Zegerid (omeprazole/sodium bicarbonate).
    Dosage forms and strengths

    Initial Post-Limit Approval

    Initial post-limit approval

    Authorization may be granted when ANY of the following initial post-limit criteria groups are met.

    Qualifying condition or risk

    • Specific gastrointestinal condition: Barrett's esophagus confirmed by biopsy OR hypersecretory syndrome, such as Zollinger-Ellison syndrome, confirmed with a diagnostic test.
    • Peptic ulcer disease or GERD indication: Endoscopically verified peptic ulcer disease OR frequent and severe symptoms of chronic GERD OR atypical symptoms or complications of GERD.
    • High GI risk: The patient is at high risk for gastrointestinal adverse events.

    Continuation Post-Limit Approval

    Continuation post-limit approval

    The same post-limit criteria apply to continued additional-quantity coverage.

    Qualifying condition or risk: The requested drug is prescribed for Barrett's esophagus confirmed by biopsy, hypersecretory syndrome confirmed with a diagnostic test, endoscopically verified peptic ulcer disease, frequent and severe chronic GERD symptoms, atypical or complicated GERD, or high risk for gastrointestinal adverse events.

    Policy Quantity Limits

    Quantity limits
    Covered drugsEach drug covered by this policy is subject to the quantity limit.
    Quantity limit90 doses
    Limit periodPer 365 days.
    Policy Summary
    PayerCVS Caremark
    PolicyPost Limit Prior Authorization Proton Pump Inhibitors
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewMar 27, 2025
    Next Review DateN/A
    Key ActionDocument a qualifying gastrointestinal condition, complication, or high risk for gastrointestinal adverse events when requesting quantities beyond 90 doses per 365 days.
    SourceLink
    On This Page
    Post-Limit Coverage CriteriaQuantity LimitPrior Authorization and Documentation RequirementsClinical BackgroundDefinitions and Referenced ProductsInitial Post-Limit ApprovalContinuation Post-Limit ApprovalPolicy Quantity Limits
    Documentation Required

    Biopsy Confirmation

    Document that Barrett's esophagus has been confirmed by biopsy when this is the basis for the request.

    • Biopsy confirmation is required when applicable.
    Documentation Required

    Diagnostic Test Confirmation

    Document hypersecretory syndrome, such as Zollinger-Ellison syndrome, confirmed with a diagnostic test when this is the basis for the request.

    • Diagnostic test confirmation is required when applicable.
    Documentation Required

    Qualifying GI Diagnosis or Complication

    Document a qualifying gastrointestinal diagnosis, symptom pattern, or complication supporting additional therapy.

    • Endoscopically verified peptic ulcer disease.
    • Frequent and severe symptoms of chronic gastroesophageal reflux disease (GERD).
    • Atypical GERD symptoms or complications, including maintenance of healing of erosive esophagitis or duodenal ulcers.
    Documentation Required

    High-Risk GI Status

    Document that the patient is at high risk for serious gastrointestinal adverse events when this is the basis for approval.

    • Risk factors include eosinophilic esophagitis, chronic NSAID therapy, history of peptic ulcer disease and/or GI bleeding, oral corticosteroid therapy, anticoagulant therapy, poor general health status, or advanced age.
    Denial Risk

    Post-Limit Criteria Not Met

    Quantities beyond the plan limit are denied when the post-limit approval criteria are not met.

    • The plan covers 90 doses per 365 days.
    • The prescriber may submit new or missing information for reconsideration.
    Denial Risk

    No Qualifying Indication or GI Risk

    Coverage is not approved without a qualifying gastrointestinal condition, GERD-related indication or complication, confirmed qualifying diagnosis, or documented high-risk GI status.

    • Requests lacking a qualifying indication or GI risk factor do not meet post-limit criteria.
    All dosage forms and strengths are included unless otherwise stated.
    Over-the-counter productsOver-the-counter (OTC) products are not included unless otherwise stated.